The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application and treatment new scientific data to the oncology community.
ASCO’s robust scientific and education meeting platform will provide attendees with live and on-demand access to top caliber scientific research presentations and slides. The online meeting experience will also offer opportunities to engage with and learn from oncology thought leaders from around the world, including interactivity and live question and answer in key sessions.
Expected pivotal trials: Keep an Eye Out For…
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). (Abstract 506)
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. (TPS603)
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress). (TPS2096)
Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC), monarchE Trial. (Abstract 517)
OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer (Abstract LBA1).
And many more!
Registration
Registration for the Meeting is open and includes access all Education and Scientific Sessions, Poster Sessions, Online Exhibits, 2021 ASCO Annual Meeting Videos and Slides, Annual Meeting Proceedings, and ASCO Educational Book – as well as access to an online platform with interactive tools and Q&A.
Access to Content
Content will be delivered in two formats: on-demand and through a scheduled broadcast. The on-demand content will be comprised of 175 sessions—formats include Oral Abstract Sessions, Poster Sessions, Poster Discussion Sessions, and track-specific Clinical Science Symposia—and will be available on June 4 at 9:00 AM EST.
The scheduled broadcast will include 48 high-impact sessions with real-time engagement, live Q&A, and unparalleled learning; these sessions will begin on June 4 at 11:00 AM EST. Sessions will be available on-demand 2 hours after airing. Search the Digital Program and the Broadcast Schedule to plan your meeting experience.
For more information, visit: ASCO 2021 Annual Meeting
